Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 6;2(3):400-412.
doi: 10.1002/jha2.202. eCollection 2021 Aug.

Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years

Björn Engelbrekt Wahlin  1   2 , Ninja Övergaard  3 , Stefan Peterson  4 , Evangelos Digkas  5 , Ingrid Glimelius  3 , Ingemar Lagerlöf  3   6 , Ann-Sofie Johansson  7 , Marzia Palma  2 , Lotta Hansson  2 , Johan Linderoth  8 , Christina Goldkuhl  9 , Daniel Molin  3
Affiliations

Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years

Björn Engelbrekt Wahlin et al. EJHaem. .

Abstract

Treatment for patients > 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and 2014 (N = 2345; median age 42 years; 691 patients were >60 years). The median follow-up time was 6.7 years. Treatment for elderly patients consisted mainly of ABVD or CHOP, and the younger patients were treated with ABVD or BEACOPP (with no survival difference). In multivariable analysis of patients > 60 years, ABVD correlated with better survival than CHOP (p = 0.027), and ABVD became more common over time among patients aged 61-70 years (p = 0.0206). Coinciding with the implementation of FDG-PET/CT, the fraction of advanced-stage disease increased in later calendar periods, also in the older patient group. Survival has improved in cHL patients > 60 years (p = 0.027), for whom ABVD seems superior to CHOP.

Keywords: classical Hodgkin lymphoma; older patients; population‐based; survival; treatment.

PubMed Disclaimer

Conflict of interest statement

Daniel Molin has received honoraria from Roche, Merck, Bristol‐Myers Squibb and Takeda. Björn Engelbrekt Wahlin has received research funding from Roche and Gilead, and he has been a consultant for Roche and Gilead. Lotta Hansson has received research grant support from Gilead and Janssen‐Cilag and honoraria from Abbvie. Ingrid Glimelius has received honoraria from Janssen‐Cilag. Marzia Palma has received research grant support from Beigene and Takeda. None of the other authors have any relevant conflict of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Overall survival. By (A) calendar period and age for all patients, (B) calendar period and age in limited (I‐IIA) stages, (C) calendar period and age in advanced (IIB‐IV) stages, (D) calendar period and age in men with advanced stages, (E) calendar period in women with advanced stages, (F) CHOP or ABVD in patients ≥ 61 years of age, (G) BEACOPP or ABVD in patients ≤ 60 years with advanced stages
FIGURE 2
FIGURE 2
Relative survival. By (A) calendar period and age in men with advanced stages, (B) calendar period in women with advanced stages, (B) CHOP or ABVD in patients ≥ 61 years of age, (C) BEACOPP or ABVD in patients ≤ 60 years with advanced stages
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548–54. - PubMed
    1. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced‐intensity chemotherapy and PET‐guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open‐label, phase 3 non‐inferiority trial. Lancet. 2012;379:1791–9. - PubMed
    1. Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET‐CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374:2419–29. - PMC - PubMed
    1. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET‐guided treatment in patients with advanced‐stage Hodgkin's lymphoma (HD18): final results of an open‐label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390:2790–802. - PubMed
    1. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol. 2009;71:222–32. - PubMed